Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
about
Hypoglycemia in Patients with Diabetes and Renal DiseaseDiabetic kidney disease: a report from an ADA Consensus ConferenceUpdate on the treatment of type 2 diabetes mellitusSystematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal ImpairmentPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.A review of the pharmacological properties of insulin degludec and their clinical relevance.Management of Hyperglycemia in Diabetic Kidney Disease.Creatinine-based equations for the adjustment of drug dosage in an obese population.'Patient-centered care' for complex patients with type 2 diabetes mellitus-analysis of two cases.Insulin degludec: pharmacokinetics in patients with renal impairment.Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.A review of gliptins for 2014.Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Special considerations for the treatment of chronic kidney disease in the elderly.Could metformin be used in patients with diabetes and advanced chronic kidney disease?Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.Estimating kidney function and use of oral antidiabetic drugs in elderly.The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction.
P2860
Q26799515-75C9E389-5E50-4FBD-801B-93860534FD51Q27012546-1F984510-CE43-49B8-B550-38FDA6AB6421Q28073342-0F64A3EF-3B82-4363-B925-4B9A3722D612Q28075368-27B66061-6C57-46DF-8F62-D61178E08517Q30249371-5470157A-AED1-429E-9DEA-90586BE36465Q34397646-37EE24CD-DF5E-4857-BE94-4BD544A53D3CQ34436383-2E7C6874-7F38-4A1D-9B9F-CDDD764FD3BFQ35953856-9001ED11-2F5B-4A20-B043-2AE480DE55B1Q36802097-68D7444C-DB4E-4FE4-B533-187D39DE8269Q37302392-CA0C8472-1784-4FB7-ABA9-E96588F82677Q37506526-6ECFDF1F-D5BE-4F17-A47B-C1B4F30FBCACQ37589626-3CF3146B-9C4F-4326-8AF4-81BBE158E40DQ38175467-B5A7CEDC-54B6-4BD9-A184-0AC3A14F348AQ38199526-C3C624E5-9FA6-4C52-8FA0-34DFACFFFB62Q38215452-5AA915FA-BED1-4E7D-B4A3-58EBA94AF672Q38236774-1B678B88-1063-4F8A-A8F2-E4F32357AFD1Q38261573-73A1A2E2-50C7-4BBF-B66F-580AD9B54FCDQ38266290-BD8378AA-BE77-4F31-8FC1-AEBBAA7C9CDEQ38267138-2A640350-D084-43D3-B9B5-B9BCE125A97CQ38335751-071423E5-F398-4BC6-817A-04EDC9CDE92DQ38389823-F082AB3F-5997-4659-A5D9-C536FDA036B3Q38497122-82FAB51D-DDD3-4EDC-A2E8-044F756A00CAQ38619164-88154B40-35A1-4D27-9CAA-28BF9D70C8B2Q38737061-39032883-7688-4EC1-A0C1-07B3F6CC19DBQ38968961-85A88DDF-2B80-4DAB-A2F7-AC45CF5B55EBQ40498481-0CCEBB33-5B12-481E-99E8-72A61E19FB72Q42665424-B90C98BF-DD2B-4CBE-A1EC-6B2E0C4DBDD6Q44314307-1F3D0891-345D-4F17-B0EE-59555D6187F0Q46304493-9DA7AC07-F5B3-41A0-9CFF-0F2A77792BB6
P2860
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetic considerations ...... s with chronic kidney disease.
@en
type
label
Pharmacokinetic considerations ...... s with chronic kidney disease.
@en
prefLabel
Pharmacokinetic considerations ...... s with chronic kidney disease.
@en
P2860
P1476
Pharmacokinetic considerations ...... s with chronic kidney disease.
@en
P2093
André J Scheen
P2860
P304
P356
10.1517/17425255.2013.777428
P407
P577
2013-03-06T00:00:00Z